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Conclusion. Radiation treatment achieved an excellent local control rate in this patient’s subgroup. This treatment must be
considered as a valid option to treat these patients, despite the high incidence of distal failure.
http://dx.doi.org/10.1016/j.rpor.2013.03.517
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Objective. Our objective is to determine the duration of clinical and radiological stabilization after PSA progression in chemother-
apy naïve mCRPC patients treated with AA, as well as analyzing its safety proﬁle in our series.
Material and methods. Retrospective analysis approved by our institution’s Ethical Committee of Clinical Investigation. 14 patients
with mCRPC who had not received prior chemotherapy in treatment with AA (1 g/24h) and prednisone (5mg/12h) have been
studied. Statistical analysis has been carried out with SPSS® version 15.
Results. Patient mean age is 75 (range 52–85), with 50% of patients having a pre-AA ECOG score ≥2. Mean treatment duration
time has been 9 months (2–12 months). PSA response, deﬁned as a 50% or higher decrease from pretreatment baseline PSA, was
observed in 75% of the patients. With a 12 month follow-up, we ﬁnd that: only 1 patient has progressed (deﬁned as clinical, radio-
logical and PSA progression). 7 patients (50%) present clinical, radiological and PSA stability. 7 patients present PSA progression,
of which 3 also associate radiological progression, 1 clinical progression and 1 with both clinical and radiological progression as
well. Treatment was suspended in 3 patients (21.4%), 1 due to PSA and radiological progression, 1 due to PSA, radiological and
clinical progression and 1 exitus due to tumor progression. In terms of treatment tolerance, no patients have presented neither
clinical nor hematological toxicity.
Conclusion. Treatment with AA in mCPCR chemo naïve patients is safe and very well tolerated, which is important considering
that most of the patients in our series were elderly patients, with average performance status, and in most cases not suitable for
other treatment options. In current clinical practice, evaluation for treatment response in mCRPC is changing, and PSA should
no longer be considered a reliable tumor marker in these patients. In our series, we have observed clinical and/or radiological
progression in only a small number of patients, normally months after PSA progression.
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Purpose. Determine biochemical response, control and disease free survival in a series of patients with long follow-up, treated
with salvage external beam radiation therapy (EBRT), the standard treatment for biochemical recurrence (BR), after radical
prostatectomy (RP).
Material and methods. Between July 2002 and July 2010, 78 patients were treated with salvage EBRT in our center. After EBRT,
BR has been deﬁned as a value of PSA≥0.2ng/ml. All patients were treated with 3D conformed EBRT. Median dose was 66Gy
(46–74Gy). 33 patients (42.3%) received hormone therapy (HT). All patients have been followed up by PSA and digital rectal
examination.
Results. The mean age was 65.6 years (SD 5.65). The preoperative PSA was <10, 10–20 or >20 in 54.3%, 35.7% and 10% respectively.
57.7% of patients were pT2, pT3a 17.9%, pT3b 15.4% and pTx 9%. The margins were negative in 43 patients (55.8%), and positive
in 31 (40.3%). 38 patients (62.3%) had a Gleason score ≤6, 13 Gleason 7 (21.3%) and 10 Gleason 8–10 (16.4%). The median PSA pre-
EBRT was 1.17ng/ml (range 0.12–19). The median post surgical PSA was 0.09ng/ml (range 0–4.2). The median follow-up was 46
months (range 22–116). Although biochemical response was seen in 63 patients (80.7%), the overall 5-year biochemical disease-
free survival rate was 55%. Multivariate analysis showed that ECOG (p=0.01) and post surgical PSA (p=0.03) were signiﬁcant
covariates predicting for bNED. Interval from surgery to BR, Gleason score, extracapsular extension, lymphovascular invasion,
perineural extension or surgical margin involvement were not associated with BR.
